46 related articles for article (PubMed ID: 19402829)
1. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
Setlur SR; Mertz KD; Rubin MA
BJU Int; 2009 May; 103(9):1293; author reply 1293. PubMed ID: 19402829
[No Abstract] [Full Text] [Related]
2. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
Jhavar S; Brewer D; Edwards S; Kote-Jarai Z; Attard G; Clark J; Flohr P; Christmas T; Thompson A; Parker M; Shepherd C; Stenman UH; Marchbank T; Playford RJ; Woodhouse C; Ogden C; Fisher C; Kovacs G; Corbishley C; Jameson C; Norman A; De-Bono J; Bjartell A; Eeles R; Cooper CS
BJU Int; 2009 May; 103(9):1256-69. PubMed ID: 19040532
[TBL] [Abstract][Full Text] [Related]
3. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
4. Medicine. Fused genes may help explain the origins of prostate cancer.
Marx J
Science; 2005 Oct; 310(5748):603. PubMed ID: 16254158
[No Abstract] [Full Text] [Related]
5. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
7. ERG upregulation and related ETS transcription factors in prostate cancer.
Rostad K; Mannelqvist M; Halvorsen OJ; Oyan AM; Bø TH; Stordrange L; Olsen S; Haukaas SA; Lin B; Hood L; Jonassen I; Akslen LA; Kalland KH
Int J Oncol; 2007 Jan; 30(1):19-32. PubMed ID: 17143509
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.
Rice KR; Chen Y; Ali A; Whitman EJ; Blase A; Ibrahim M; Elsamanoudi S; Brassell S; Furusato B; Stingle N; Sesterhenn IA; Petrovics G; Miick S; Rittenhouse H; Groskopf J; McLeod DG; Srivastava S
Clin Cancer Res; 2010 Mar; 16(5):1572-6. PubMed ID: 20160063
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.
Cerveira N; Ribeiro FR; Peixoto A; Costa V; Henrique R; Jerónimo C; Teixeira MR
Neoplasia; 2006 Oct; 8(10):826-32. PubMed ID: 17032499
[TBL] [Abstract][Full Text] [Related]
10. Potential for targeted therapy in prostate cancers with ERG abnormalities.
Williamson SR; Cheng L
Asian J Androl; 2011 Nov; 13(6):781-2. PubMed ID: 21785441
[No Abstract] [Full Text] [Related]
11. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.
Liu W; Chang B; Sauvageot J; Dimitrov L; Gielzak M; Li T; Yan G; Sun J; Sun J; Adams TS; Turner AR; Kim JW; Meyers DA; Zheng SL; Isaacs WB; Xu J
Genes Chromosomes Cancer; 2006 Nov; 45(11):1018-32. PubMed ID: 16897747
[TBL] [Abstract][Full Text] [Related]
12. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
14. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.
Liu W; Ewing CM; Chang BL; Li T; Sun J; Turner AR; Dimitrov L; Zhu Y; Sun J; Kim JW; Zheng SL; Isaacs WB; Xu J
Genes Chromosomes Cancer; 2007 Nov; 46(11):972-80. PubMed ID: 17654723
[TBL] [Abstract][Full Text] [Related]
15. Emerging biological observations in prostate cancer.
Shah S; Small E
Expert Rev Anticancer Ther; 2010 Jan; 10(1):89-101. PubMed ID: 20014889
[TBL] [Abstract][Full Text] [Related]
16. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.
Wang J; Cai Y; Yu W; Ren C; Spencer DM; Ittmann M
Cancer Res; 2008 Oct; 68(20):8516-24. PubMed ID: 18922926
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
19. ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22).
Moore SD; Offor O; Ferry JA; Amrein PC; Morton CC; Dal Cin P
Leuk Res; 2006 Aug; 30(8):1037-42. PubMed ID: 16303180
[TBL] [Abstract][Full Text] [Related]
20. Prioritizing precision medicine for prostate cancer.
Attard G; Beltran H
Ann Oncol; 2015 Jun; 26(6):1041-1042. PubMed ID: 25862438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
